Galapagos reports on historic first quarter 2019
Key Q1 2019 results: Group revenues of €40.9 million Operating loss €53.2 million Net loss of €48.7 million End of first quarter cash and cash equivalents €1.2 billion Competitive safety and efficacy results with filgotinib in FINCH 1 and 3 Phase 3 trials …